GENWORTH FINANCIAL INC (GNW) stock intrinsic value fair value estimate & owner earnings analysis

Genworth Financial is a holding company whose value rests almost entirely on its roughly 81% stake in Enact Holdings, a publicly listed U.S. private mortgage insurer. Enact protects lenders against default on low-down-payment home loans; it wrote $51.5 billion of new insurance in 2025 and its insured portfolio grew about 2%. Genworth also owns a large legacy block of long-term care, life and annuity policies (the Closed Block, carrying about $55 billion of policy reserves) held in separately regulated insurance companies, plus CareScout, a young aging-care services business that began selling a new long-term care insurance product, Care Assurance, in October 2025. The central judgement: in its 2025 annual report Genworth says it manages the legacy insurers on a standalone basis and does not expect any dividends or other capital from them; the holding company's cash comes from Enact. The legacy block's accounting losses (an operating loss of $317 million in 2025, $214 million in 2024 and $430 million in 2023, driven by an aging long-term care book and reserve assumption updates) therefore do not reach shareholders, but neither does any of its capital. We value it at zero in all three cases: nothing we can point to, such as a dividend plan or sale agreement, gives it a positive value, and we found no commitment requiring the parent to fund its losses. How we measured earnings. For a life and long-term care insurer, reported operating cash flow is misleading. In 2025 it was $327 million, but it excludes about $540 million of policy charges deducted from universal life account balances and about $450 million of partnership income and bond accretion that settle elsewhere in the cash flow statement, while including a $908 million rise in reserves that is really a cost. We therefore measured owner earnings as net income plus non-cash charges (mainly amortization of acquisition costs capitalized long ago) less capital spending. On that consolidated basis Genworth earned $0.61, $0.85 and $0.71 per share in 2023-2025. Figures for 2019-2022 were higher ($1.70-$2.82) but are on pre-2023 insurance accounting and include businesses since sold, so they are not comparable. Setting aside the ring-fenced legacy block, the earnings that actually belong to shareholders - Genworth's share of Enact less holding-company interest, overhead and CareScout costs - were $471 million, $487 million and $461 million, about $1.00-$1.11 per share. That figure is flattered by one-offs. Enact released $252 million of reserves in 2024 and $200 million in 2025 as delinquent borrowers cured better than expected, while new delinquencies are rising (50,481 in 2025 versus 48,537 in 2024) as newer loans season. Excluding releases, Genworth's share of Enact's earnings was about $430 million in 2025, up about 1.4% from 2024. Genworth also put $85 million of capital into CareScout Insurance in 2025 and expects smaller amounts over the next few years. Enact expects to return about $500 million to shareholders in 2026, about $405 million of it to Genworth, which is consistent with our starting point. Base case (about $14.29 per share): Enact's underlying earnings grow 1.5% a year - the pace of the latest year, consistent with 2% insured-portfolio growth and slightly lower premium rates - with about 12% retained to fund the capital that growth requires. Reserve releases fade from about $100 million pre-tax next year to $40 million a year from year three. Holding-company costs stay near $100 million a year, with CareScout capital of $40 million a year for three years and $20 million thereafter. That leaves roughly $300 million a year available to shareholders now, rising to about $345 million by year ten, held flat after that on the strength of Enact's established position in a market where federally backed mortgage buyers require credit protection on low-down-payment loans. Cash flows are discounted at 6%. Bear case (about $9.77): a housing-credit downturn deeper than 2020, when Enact's net income fell from $678 million to $370 million - here Enact earns only 30% of normal in year two and 70% in year three - followed by underlying earnings shrinking 1% a year as premium rates keep slipping, with no further reserve releases. CareScout absorbs $85 million a year for five years with no return, and holding-company costs rise to $110 million as the $539 million of floating-rate junior notes reprice. Holding-company cash of $234 million at the end of 2025 covers the stress years, and no holding-company debt matures until June 2034. Bull case (about $17.58): Enact's earnings grow 3% a year as the insured portfolio and investment income grow faster, strong cure performance keeps producing about $150 million a year of reserve releases as it has in recent years, CareScout's capital needs fall to about $10 million a year as management indicates, and holding-company costs ease to $90 million. The legacy block still contributes nothing. Margin-of-safety price: $8.75. Earnings depend on the housing credit cycle and the structure is complex - a controlled public subsidiary, a very large ring-fenced legacy block and a start-up - so the margin-of-safety price sits roughly 40% below the base case, which also places it below the bear case. What would make this wrong: a severe housing crisis on the scale of 2008-2011, when U.S. mortgage insurers suffered heavy losses, would push value below the bear case; a change in how Fannie Mae and Freddie Mac use private mortgage insurance would impair Enact's franchise; and any move by the parent to support the legacy insurers with cash would turn the zero we assign them into a negative. On the other side, no value is credited for any eventual release of capital from the legacy block. Capital spending is not separately disclosed; we used the company's small 'other' investing outflows (about $50-56 million a year) as a proxy.